Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07790523 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

Study acronym: DAN-COMBO
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.
Trial Details
NCT Number NCT07790523
Lead Sponsor Tor Biering-Sørensen
Collaborators: ModernaTX, Inc.
Conditions
(from sponsor)		 COVID-19, Influenza
Related terms COVID-19, Influenza, Human, Respiratory Tract Diseases
Enrollment 410,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov